Patent intelligence · US
US 9765378
Preparation method of new recombinant antibacterial polypeptide medicine
Preparation method of new recombinant antibacterial polypeptide medicine
Patent details — US 9765378
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 19, 2017
- Expiration
- Sep 14, 2037
- Claims
- 12
- CPC classes
- A61P, A61P31/00, A61P31/04
Quick answer
US 9765378 (Preparation method of new recombinant antibacterial polypeptide medicine) is held by Creative Trio Biotech (Beijing) Co., Ltd.. Status: granted. Granted Sep 19, 2017. Expires Sep 14, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61P, A61P31/00, A61P31/04
More from Creative Trio Biotech (Beijing) Co., Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12234288
Immunogenic arginase 2 polypeptides
granted -
US 12233103
Indoleamine 2,3-dioxygenase based immunotherapy
granted -
US 12215135
PDL2 compounds
granted -
US 12194081
ARGINASE1 polypeptides
granted -
US 12187782
PDL1 peptides for use in cancer vaccines
granted -
US 12077785
Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof
granted -
US 11981944
Immunogenic arginase peptides
granted -
US 11878053
Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
granted
Frequently asked questions
What is US patent 9765378?
US 9765378 (Preparation method of new recombinant antibacterial polypeptide medicine) is held by Creative Trio Biotech (Beijing) Co., Ltd.. Status: granted. Granted Sep 19, 2017. Expires Sep 14, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9765378?
Creative Trio Biotech (Beijing) Co., Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does US 9765378 expire?
Our index shows an expiration date of Sep 14, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.